Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the underlying pathophysiology linked to its causal gene,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Rev Drug Discov
Main Authors: Berry-Kravis, Elizabeth M., Lindemann, Lothar, Jønch, Aia E., Apostol, George, Bear, Mark F., Carpenter, Randall L., Crawley, Jacqueline N., Curie, Aurore, Des Portes, Vincent, Hossain, Farah, Gasparini, Fabrizio, Gomez-Mancilla, Baltazar, Hessl, David, Loth, Eva, Scharf, Sebastian H., Wang, Paul P., Von Raison, Florian, Hagerman, Randi, Spooren, Will, Jacquemont, Sébastien
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6904225/
https://ncbi.nlm.nih.gov/pubmed/29217836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrd.2017.221
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados